MathWorks bringing 50 jobs to Galway

While a US pharmaceutical company is creating 40 positions in Dublin...

MathWorks has announced it will create 50 jobs at its new shared sales and services centre in Galway.

The Massachusetts-based mathematical computer software firm is already looking to fill more than 20 of the positions.

MathWorks manufactures technologies such as MATLAB and Simulink which are used in the automotive, aerospace, communications, electronics and industrial automation industries.

Jobs Minister Mary Mitchell O'Connor said:

"We are all aware that specialist software is a huge growth area and the generator of quality jobs. This initiative builds on our success in developing a thriving software sector in Ireland over recent years following our ongoing investment in developing appropriate skills."

MathWorks managing director Richard Haxby said Ireland was selected due to its "core competency" in shared sales and services centre operations, while Galway's "access to a diverse multi-lingual workforce" and "university system" made it attractive.

For more information on the jobs, click here.

Meanwhile, US pharma firm Mallinckrodt will create 40 new jobs in Dublin as it opens a new €10m research and development centre in Blanchardstown.

The new premises will house the company's global device engineering.

Mallinckrodt has invested a total of €85m in its Dublin site, with the new positions set to bring its total Dublin workforce up to 120 by next year.

Mallinckrodt chief executive Mark Trudeau said:

“Today’s dedication and announcement reaffirms Ireland’s strategic importance to Mallinckrodt as we continue with our transition to become a high-growth, global specialty pharmaceutical business.

"We are in the process of bringing global R&D activities for medical devices to this location and the team will focus on developing systems for delivery of certain specialty pharmaceutical therapies in our portfolio."

Dublin West TD Leo Varadkar said of the investment:

"This company is at the cutting edge of new and innovative treatments and the range of facilities being developed here is an exciting development.

"The Government has worked hard to create the right conditions for cutting edge pharma and biopharma companies to locate in Ireland and the provision of high quality jobs in this new research and development facility is very welcome."